Pharmacogenetics of membrane transporters: A review of current approaches

Methods in Molecular Biology

Volumn 448, Issue , 2008, Pages 41-62

  Sissung, Tristan M ^a   Gardner, Erin R ^b   Gao, Rui ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

ABCB1; ABCC1; ABCC2; ABCG2; OATP1B1; OATP1B3; Polymor phisms; Transport

Indexed keywords

EID: 84934437989     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-205-2_4     Document Type: Article

References (95)

1. Borst, P., Evers, R., Kool, M., and Wijnholds, J. (2000) A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92, 1295-1302.
2. Dean, M., Rzhetsky, A., and Allikmets, R. (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166.
3. Gottesman, M. M., and Ambudkar, S. V. (2001) Overview: ABC transporters and human disease. J. Bioenerg. Biomembr. 33, 453-458.
4. Lepper, E. R., Nooter, K., Verweij, J., Acharya, M. R., Figg, W. D., and Sparreboom, A. (2005) Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics. 6, 115-138.
5. Fojo, A. T., Shen, D. W., Mickley, L. A., Pastan, I., and Gottesman, M. M. (1987) Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrugresistance gene. J. Clin. Oncol. 5, 1922-1927.
6. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., et al. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458-3464.
7. Schellens, J. H., Malingre, M. M., Kruijtzer, C. M., et al. H. (2000) Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur. J. Pharm. Sci. 12, 103-110.
8. Schinkel, A. H., Mayer, U., Wagenaar, E., et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 94, 4028-4033.
9. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 84, 7735-7738.
10. Gottesman, M. M., and Ambudkar, S. V. (2001) Overview: ABC transporters and human disease. J. Bioenerg. Biomembr. 33, 453-458.
11. Xiao, J. J., Foraker, A. B., Swaan, P. W., et al. (2005) Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J. Pharmacol. Exp. Ther. 313, 268-276.
12. Chaudhary, P. M., and Roninson, I. B. (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 66, 85-94.
13. Eichelbaum, M., Fromm, M. F., and Schwab, M. (2004) Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26, 180-185.
14. Fromm, M. F. (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25, 423-429.
15. Meissner, K., Sperker, B., Karsten, C., et al. (2002) Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J. Histochem. Cytochem. 50, 1351-1356.
16. Rao, V. V., Dahlheimer, J. L., Bardgett, M. E., et al. (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. U. S. A. 96, 3900-3905.
17. Saito, T., Zhang, Z. J., Ohtsubo, T., et al. (2001) Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs. Acta Otolaryngol. 121, 735-742.
18. Wijnholds, J., deLange, E. C., Scheffer, G. L., et al. (2000) Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood - cerebrospinal fluid barrier. J. Clin. Invest. 105, 279-285.
19. Borst, P., Evers, R., Kool, M., and Wijnholds, J. (1999) The multidrug resistance protein family. Biochim. Biophys. Acta. 1461, 347-357.
20. Cascorbi, I. (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112, 457-473.
21. Deeley, R. G., and Cole, S. P. (2006) Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 580, 1103-1111.
22. Ho, R. H., and Kim, R. B. (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78, 260-277.
23. Smith, N. F., Figg, W. D., and Sparreboom, A. (2005) Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin. Drug Metab. Toxicol. 1, 429-445.
24. Kurata, Y., Ieiri, I., Kimura, M., et al. (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 72, 209-219.
25. Meissner, K., Sperker, B., Karsten, C., et al. (2002) Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J. Histochem. Cytochem. 50, 1351-1356.
26. Tanabe, M., Ieiri, I., Nagata, N., et al. (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297, 1137-1143.
27. Yi, S. Y., Hong, K. S., Lim, H. S., et al. (2004) A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. 76, 418-427.
28. Sun, J., He, Z. G., Cheng, G., Wang, S. J., Hao, X. H., and Zou, M. J. (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med. Sci. Monit. 10, RA5-RA14.
29. Imai, Y., Nakane, M., Kage, K., et al. (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1, 611-616.
30. Kobayashi, D., Ieiri, I., Hirota, T., et al. (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. 33, 94-101.
31. Kolwankar, D., Glover, D. D., Ware, J. A., and Tracy, T. S. (2005) Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab. Dispos. 33, 524-529.
32. Kondo, C., Suzuki, H., Itoda, M., et al. (2004) Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 21, 1895-1903.
33. Sparreboom, A., Gelderblom, H., Marsh, S., et al. (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther. 76, 38-44.
34. Mizuarai, S., Aozasa, N., and Kotani, H. (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int. J. Cancer 109, 238-246.
35. de Jong, F. A., Marsh, S., Mathijssen, R. H., et al. (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 10, 5889-5894.
36. Imai, Y., Nakane, M., Kage, K., et al. (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1, 611-616.
37. Kondo, C., Suzuki, H., Itoda, M., et al. (2004) Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 21, 1895-1903.
38. Allen, J. D., Jackson, S. C., and Schinkel, A. H. (2002) A mutation hot spot in the BCRPl (ABCG2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res. 62, 2294-2299.
39. Honjo, Y., Hrycyna, C. A., Yan, Q. W., et al. (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP- overexpressing cells. Cancer Res. 61, 6635-6639.
40. Robey, R. W., Honjo, Y., Morisaki, K., et al. (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 89, 1971-1978.
41. Robey, R. W., Steadman, K., Polgar, O., et al. (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 64, 1242-1246.
42. Letourneau, I. J., Deeley, R. G., and Cole, S. P. (2005) Functional characterization of nonsynonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet. Genomics. 15, 647-657.
43. Oselin, K., Mrozikiewicz, P. M., Gaikovitch, E., Pahkla, R., and Roots, I. (2003) Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur. J. Clin. Pharmacol. 59, 347-350.
44. Tirona, R. G., Leake, B. F., Merino, G., and Kim, R. B. (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675.
45. Nozawa, T., Nakajima, M., Tamai, I., et al. (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302, 804-813.
46. Colburn, W. A. (2003) Biomarkers in drug discovery and development: from target identification through drug marketing. J. Clin. Pharmacol. 43, 329-341.
47. Cole, S. P., Bhardwaj, G., Gerlach, J. H., et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258, 1650-1654.
48. Hesselink, D. A., van Schaik, R. H., van der Heiden, I. P., et al. (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245-254.
49. Noe, B., Hagenbuch, B., Stieger, B., and Meier, P. J. (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. U. S. A. 94, 10346-10350.
50. Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., and Kim, R. B. (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27, 866-871.
51. Aszalos, A. (2004) P-glycoprotein-based drug-drug interactions: preclinical methods and relevance to clinical observations. Arch. Pharm. Res. 27, 127-135.
52. Smith, N. F., Acharya, M. R., Desai, N., Figg, W. D., and Sparreboom, A. (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther. 4, 815-818.
53. + natural killer cells. Pharmacogenetics. 11, 293-298.
54. Schaefer, M., Roots, I., and Gerloff, T. (2005) In vitro transport characteristics discriminate wildtype mdr1 (abcb1) from ala893ser and ala893thr polymorphisms. Eur. J. Clin. Pharmacol. 61, 718.
55. Ishikawa, T., Sakurai, A., Kanamori, Y., et al. (2005) High-speed screening of human ATP-binding cassette transporter function and genetic polymorphisms: new strategies in pharmacogenomics. Methods Enzymol. 400, 485-510.
56. Morisaki, K., Robey, R. W., Ozvegy-Laczka, C., et al. (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 56, 161-172.
57. Robey, R. W., Honjo, Y., Morisaki, K., et al. (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer. 89, 1971-1978.
58. Zhang, Y., Gupta, A., Wang, H., et al. (2005) BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm. Res. 22, 2023-2034.
59. Nakamura, Y., Oka, M., Soda, H., et al. (2005) Gefitinib ("Iressa," ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res. 65, 1541-1546.
60. Iwai, M., Suzuki, H., Ieiri, I., Otsubo, K., and Sugiyama, Y. (2004) Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics. 14, 749-757.
61. Michalski, C., Cui, Y., Nies, A. T., et al. (2002) A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem. 277, 43058-43063.
62. Nozawa, T., Minami, H., Sugiura, S., Tsuji, A., and Tamai, I. (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33, 434-439.
63. Tirona, R. G., Leake, B. F., Wolkoff, A. W., and Kim, R. B. (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304, 223-228.
64. Hoffmeyer, S., Burk, O., von Richter, O., et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 97, 3473-3478.
65. Song, P., Lamba, J. K., Zhang, L., et al. (2006) G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J. Clin. Pharmacol. 46, 373-379.
66. Meissner, K., Jedlitschky, G., Meyer zu Schwabedissen, H., et al. (2004) Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics. 14, 381-385.
67. Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L., and Sadee, W. (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics. 15, 693-704.
68. Zamber, C. P., Lamba, J. K., Yasuda, K., et al. (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics. 13, 19-28.
69. Kimchi-Sarfaty, C., Gribar, J. J., and Gottesman, M. M. (2002) Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62, 1-6.
70. Lin, J. H., and Yamazaki, M. (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42, 59-98.
71. Schinkel, A. H., Smit, J. J., van Tellingen, O., et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77, 491-502.
72. Sparreboom, A., van Asperen, J., Mayer, U., et al. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U. S. A. 94, 2031-2035.
73. Smit, J. W., Huisman, M. T., van Tellingen, O., Wiltshire, H. R., and Schinkel, A. H. (1999) Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 104, 1441-1447.
74. Allen, J. D., Brinkhuis, R. F., van Deemter, L., Wijnholds, J., and Schinkel, A. H. (2000) Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 60, 5761-5766.
75. Allen, J. D., Brinkhuis, R. F., Wijnholds, J., and Schinkel, A. H. (1999) The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 59, 4237-4241.
76. Gallo, J. M., Li, S., Guo, P., Reed, K., and Ma, J. (2003) The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 63, 5114-5117.
77. Ejsing, T. B., Pedersen, A. D., and Linnet, K. (2005) P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum. Psychopharmacol. 20, 493-500.
78. Doran, A., Obach, R. S., Smith, B. J., et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. 33, 165-174.
79. Johne, A., Kopke, K., Gerloff, T., et al. (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72, 584-594.
80. Verstuyft, C., Schwab, M., Schaeffeler, E., et al. (2003) Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. 58, 809-812.
81. Sakaeda, T. (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab. Pharmacokinet. 20, 391-414.
82. Lin, S. K., Su, S. F., and Pan, C. H. (2006) Higher plasma drug concentration in clozapinetreated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther. Drug Monit. 28, 303-307.
83. Sissung, T. M., Mross, K., Steinberg, S. M., et al. (2006) Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer. 42, 2893-2896.
84. Niemi, M., Schaeffeler, E., Lang, T., et al. (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 14, 429-440.
85. Niemi, M., Neuvonen, P. J., Hofmann, U., et al. (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics. 15, 303-309.
86. Tachibana-Iimori, R., Tabara, Y., Kusuhara, H., et al. (2004) Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19, 375-380.
87. Schaefer, M., Roots, I., and Gerloff, T. (2006) In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet. Genomics. 16, 855-861.
88. Kim, R. B., Leake, B. F., Choo, E. F., et al. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199.
89. Goh, B. C., Lee, S. C., Wang, L. Z., et al. (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20, 3683-3690.
90. Isla, D., Sarries, C., Rosell, R., et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15, 1194-1203.
91. Puisset, F., Chatelut, E., Dalenc, F., et al. (2004) Dexamethasone as a probe for docetaxel clearance. Cancer Chemother. Pharmacol. 54, 265-272.
92. Wils, P., Phung-Ba, V., Warnery, A., et al. (1994) Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 48, 1528-1530.
93. Sparreboom, A., Loos, W. J., Burger, H., et al. (2005) Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther. 4, 650-658.
94. Gardner, E. R., Burger, H., van Schaik, R. H., et al. (2006) Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin. Pharmacol. Ther. 80, 192-201.
95. Mwinyi, J., Johne, A., Bauer, S., Roots, I., and Gerloff, T. (2004) Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415-421.